Search results
Results From The WOW.Com Content Network
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors (formerly known as carcinoid tumors). [1] The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting ...
It is a relatively rare cancer and is diagnosed in approximately 1/100000 people every year. In recent decades the incidence has increased. [1] The prognosis is comparatively good with a median survival of more than 8 years. [2] The disease was named by Siegfried Oberndorfer, a German pathologist, in 1907. [3]
Carcinoid tumors are the most common malignant tumor of the appendix, but they are most commonly associated with the small intestine, and they can also be found in the rectum and stomach. They are known to grow in the liver, but this finding is usually a manifestation of metastatic disease from a primary carcinoid occurring elsewhere in the body.
Enterochromaffin cells, which give rise to carcinoid tumors, were identified in 1897 by Nikolai Kulchitsky and their secretion of serotonin was established in 1953 [105] when the "flushing" effect of serotonin had become clinically recognized. Carcinoid heart disease was identified in 1952, and carcinoid fibrosis in 1961. [105]
Related changes; Upload file; Special pages; ... Pulmonary carcinoid tumour is a neuroendocrine tumour of the lung. [1] ... (cancer.org) This page was last ...
“When systemic and chronic inflammation accompanies these underlying diseases, it can affect multiple organ systems, manifesting as fatigue, muscle weakness, digestive disturbances, joint pain ...
Primary pellagra is due to a diet that does not contain enough niacin and tryptophan. [1] Secondary pellagra is due to a poor ability to use the niacin within the diet. [1] This can occur as a result of alcoholism, long-term diarrhea, carcinoid syndrome, Hartnup disease, and a number of medications such as isoniazid. [1]
[25] [26] The safety and effectiveness of everolimus in carcinoid tumors have not been established. [25] [26] sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.